RIO DE JANEIRO, BRAZIL - An announcement by Pfizer Monday that interim reports of its COVID-19 vaccine show a 90 percent efficacy made headlines around the world in a welcome break from grim news about the progress of the disease. The news boosted the DOW to a gain of nearly 1500 points by mid-morning Monday, November 9th. Indeed it is a remarkable level of effectiveness.
"Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine's ability to prevent COVID . . .